Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company’s headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Type
Public
HQ
Petaluma, US
Size (employees)
38 (est)+12%
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is headquartered in Petaluma, US
Report incorrect company information

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Office Locations

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) has offices in Petaluma and Herten
Petaluma, US (HQ)
1129 N McDowell Blvd
Herten, NL
6049 LX Herten/Roermond
Show all (2)
Report incorrect company information

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financials and Metrics

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) Financials

Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s revenue was reported to be $12.83 m in FY, 2017 which is a 15% decrease from the previous period.
USD

Revenue (Q2, 2018)

4.3 m

Gross profit (Q2, 2018)

1.8 m

Gross profit margin (Q2, 2018), %

42.7%

Net income (Q2, 2018)

(2.9 m)

EBIT (Q2, 2018)

(2.9 m)

Market capitalization (5-Dec-2016)

20.9 m

Closing share price (5-Dec-2016)

4.9

Cash (30-Sep-2017)

10 m

EV

10.9 m
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences)'s current market capitalization is $20.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

13.7 m13.9 m15.1 m12.8 m

Revenue growth, %

1%9%(15%)

Cost of goods sold

5.3 m6.6 m7.9 m7.2 m

Gross profit

8.4 m7.3 m7.2 m5.7 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

4.1 m3.3 m3.4 m3.3 m3.2 m3.7 m4.1 m3.8 m3.8 m4.1 m3.4 m3.8 m4.3 m

Cost of goods sold

1.4 m1.2 m1.5 m1.5 m1.6 m1.8 m2 m2.3 m1.9 m2 m1.7 m2.1 m2.5 m

Gross profit

2.7 m2.1 m1.9 m1.7 m1.7 m1.9 m2.1 m1.5 m1.9 m2.1 m1.7 m1.8 m1.8 m

Gross profit Margin, %

66%64%56%53%51%51%52%40%50%51%51%46%43%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.5 m6.1 m7.5 m17.5 m

Accounts Receivable

1.8 m1.5 m2.3 m2.1 m

Inventories

647 k592 k1.5 m2.2 m

Current Assets

9.5 m9.6 m12.9 m22.6 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

3.2 m3.4 m5 m3.5 m2.2 m8.8 m8 m6.1 m5 m3.3 m19 m12.6 m10 m

Accounts Receivable

2.4 m2.6 m2 m2.1 m1.4 m2.5 m2.6 m2.7 m2.6 m2.3 m2 m2.7 m3 m

Inventories

749 k970 k1.3 m1.2 m1.4 m1.5 m1.7 m1.6 m2 m2.1 m2.1 m2.4 m2.6 m

Current Assets

6.9 m7.5 m8.7 m7.3 m5.2 m13.3 m12.7 m11.1 m10.5 m8.4 m25.1 m19.3 m17.2 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

3.7 m(8.2 m)(10.2 m)9.3 m

Depreciation and Amortization

284 k253 k244 k248 k

Inventories

(126 k)(627 k)(382 k)(675 k)

Accounts Payable

848 k222 k429 k(58 k)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(1.4 m)(611 k)(70 k)(718 k)(5.9 m)(2.3 m)(1.8 m)(3.1 m)(2.6 m)(1.9 m)16.2 m

Accounts Payable

943 k1.1 m942 k1.2 m1.2 m1.5 m1.4 m1.3 m1.1 m
USDY, 2017

EV/EBIT

-3.8 x

EV/CFO

-1.3 x

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information